Mutant ras peptide vaccine - GlaxoSmithKline

Drug Profile

Mutant ras peptide vaccine - GlaxoSmithKline

Latest Information Update: 06 Sep 2006

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 06 Sep 2006 Discontinued - Phase-II for Colorectal cancer in USA (SC)
  • 06 Sep 2006 Discontinued - Phase-II for Pancreatic cancer in USA (SC)
  • 07 Jul 2003 Phase-II clinical trials in Colorectal cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top